BTIG Research Issues Pessimistic Forecast for Zevra Therapeutics (NASDAQ:ZVRA) Stock Price

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) had its target price reduced by research analysts at BTIG Research from $24.00 to $21.00 in a research report issued on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research‘s price objective would suggest a potential upside of 124.65% from the stock’s current price.

ZVRA has been the topic of several other research reports. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research report on Thursday, August 6th. William Blair raised Zevra Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. Citizens Jmp raised their target price on shares of Zevra Therapeutics from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, August 6th. Canaccord Genuity Group cut their target price on shares of Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating on the stock in a report on Monday, July 27th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Zevra Therapeutics in a report on Wednesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $24.57.

Check Out Our Latest Research Report on ZVRA

Zevra Therapeutics Stock Performance

Shares of ZVRA stock traded down $1.81 during mid-day trading on Friday, hitting $9.35. 1,866,404 shares of the stock were exchanged, compared to its average volume of 1,225,129. The stock’s fifty day simple moving average is $11.06 and its two-hundred day simple moving average is $10.83. The stock has a market capitalization of $556.30 million, a price-to-earnings ratio of 7.86 and a beta of 1.01. Zevra Therapeutics has a 12-month low of $8.01 and a 12-month high of $15.03.

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.16 by $0.10. The business had revenue of $37.76 million for the quarter, compared to analysts’ expectations of $37.08 million. Zevra Therapeutics had a return on equity of 54.64% and a net margin of 52.80%. On average, research analysts expect that Zevra Therapeutics will post 0.88 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Zevra Therapeutics news, CEO Neil McFarlane sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $11.25, for a total transaction of $225,000.00. Following the completion of the sale, the chief executive officer directly owned 417,225 shares of the company’s stock, valued at $4,693,781.25. This represents a 4.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Integrated Wealth Concepts LLC purchased a new stake in shares of Zevra Therapeutics during the second quarter worth approximately $28,000. Fulcrum Asset Management LLP acquired a new position in Zevra Therapeutics in the 3rd quarter valued at $31,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in Zevra Therapeutics in the 3rd quarter valued at $33,000. State of Alaska Department of Revenue acquired a new position in Zevra Therapeutics in the 3rd quarter valued at $44,000. Finally, State of Wyoming purchased a new position in Zevra Therapeutics during the 3rd quarter worth $81,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

(Get Free Report)

Zevra Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for rare diseases. Its work includes research and development as well as bringing therapies to patients with limited treatment options. The company’s products include MIPLYFFA (arimoclomol), approved in the United States for neurological manifestations of Niemann-Pick disease type C, and OLPRUVA (sodium phenylbutyrate), a treatment for certain urea cycle disorders. Zevra also advances investigational therapies for rare and complex conditions.

See Also

Analyst Recommendations for Zevra Therapeutics (NASDAQ:ZVRA)

Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.